EAM
CBAY

EverPoint Asset Management’s Cymabay Therapeutics CBAY Stock Holding History

EverPoint Asset Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-468,099
Closed -$1.26M – 550
2015
Q2 		$1.26M Sell
468,099
-331,901
-41% -$1.36M 0.02% 404
2015
Q1 		$5.54M Buy
800,000
+52,806
+7% +$507K 0.1% 254
2014
Q4 		$7.34M Buy
+747,194
New +$6.01M 0.17% 196

Other funds holding CBAY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

EverPoint Asset Management's CBAY Position: Q3 2015 in Review

EverPoint Asset Management sold out of Cymabay Therapeutics (CBAY) in Q3 2015, closing a stake of 468,099 shares — an estimated $1.26M sold.

EverPoint Asset Management first reported a position in CBAY in Q4 2014 and held it in 3 quarters. The position peaked at $7.34M in Q4 2014. 35 funds tracked by Wall St. Rank hold CBAY as of Q3 2015.

  • EverPoint Asset Management reported no remaining Cymabay Therapeutics position as of Q3 2015 after selling out during the quarter.
  • EverPoint Asset Management sold 468,099 Cymabay Therapeutics shares in Q3 2015, an estimated $1.26M.
  • EverPoint Asset Management first reported a position in Cymabay Therapeutics in Q4 2014 and held it in 3 quarters.
  • EverPoint Asset Management's Cymabay Therapeutics position peaked at $7.34M in Q4 2014.
  • 35 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2015.

Based on EverPoint Asset Management's 13F filing for Q3 2015, filed 16 Nov 2015.